Science
Novartis Data Shows Kisqali Significantly Cuts Recurrence Risk in Younger Breast Cancer Patients
Across the study population, Kisqali consistently lowered recurrence risk irrespective of age or menopausal status, reinforcing its role as a cornerstone adjuvant treatment.
Subscriber access
Full story for subscribers
Sign in with your subscribed Google account to read the full article.
Checking your access…